Rivaroxaban, the first oral, direct factor Xa inhibitor.
Venous thromboembolism (VTE) is a major cause of death in hospitalized patients. In particular, patients undergoing elective major lower-limb orthopaedic surgery are at high risk of developing post-operative VTE. Rivaroxaban, a new oral anticoagulant, has been shown to be more effective than enoxaparin in reducing total and symptomatic VTE with similar major and non-major bleeding rates in patients undergoing elective total hip or total knee replacement.
Fassiadis
Nicholas
N
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors; D006801:Humans; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000069552:Rivaroxaban; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D054556:Venous Thromboembolism / Q000188:drug therapy*
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban